Wiki source code of Neurodiagnoses

Version 10.1 by manuelmenendez on 2025/01/27 23:52

version	line-number	content
1.1	1	(% class="jumbotron" %)
	2	(((
	3	(% class="container" %)
	4	(((
7.1	5	= //A new tridimensional diagnostic framework for CNS conditions// =
1.1	6
6.1	7	This project is focused on developing a novel nosological and diagnostic framework for neurological diseases by using advanced AI techniques and integrating data from neuroimaging, biomarkers, and biomedical ontologies.
	8	We aim to create a structured, interpretable, and scalable diagnostic tool.
1.1	9	)))
	10	)))
	11
	12	(% class="row" %)
	13	(((
	14	(% class="col-xs-12 col-sm-8" %)
	15	(((
6.1	16	= What is this about and what can I find here? =
1.1	17
9.1	18	== Overview ==
6.1	19
	20	The //Tridimensional Diagnostic Framework// redefines how neurodegenerative diseases (NDDs) are classified by focusing on:
	21
	22	* Axis 1: Etiology (genetic/sporadic and environmental factors).
	23	* Axis 2: Molecular Markers (biomarkers and proteinopathies).
	24	* Axis 3: Neuroanatomoclinical correlations (linking clinical symptoms to structural changes in the nervous system).
	25
	26	This methodology enables:
	27
	28	* Greater precision in diagnosis.
	29	* Integration of incomplete datasets using AI-driven probabilistic modeling.
	30	* Stratification of patients for personalized treatment.
	31
9.1	32	== Diagnostic Axes ==
6.1	33
	34	* (((
	35	Axis 1: Etiology
	36
	37	* //Description//: Focuses on genetic and sporadic causes, identifying risk factors and potential triggers.
	38	* //Examples//: APOE ε4 as a genetic risk factor, or cardiovascular health affecting NDD progression.
	39	* //Tests//: Genetic testing, lifestyle and cardiovascular screening.
	40	)))
	41	* (((
	42	Axis 2: Molecular Markers
	43
	44	* //Description//: Analyzes primary (amyloid-beta, tau) and secondary biomarkers (NFL, GFAP) for tracking disease progression.
	45	* //Examples//: CSF amyloid-beta concentrations to confirm Alzheimer’s pathology.
	46	* //Tests//: Blood/CSF biomarkers, PET imaging (Tau-PET, Amyloid-PET).
	47	)))
	48	* (((
	49	Axis 3: Neuroanatomoclinical
	50
	51	* //Description//: Links clinical symptoms to neuroanatomical changes, such as atrophy or functional impairments.
	52	* //Examples//: Hippocampal atrophy correlating with memory deficits.
	53	* //Tests//: MRI volumetrics, FDG-PET, neuropsychological evaluations.
	54	)))
	55
9.1	56	== Applications ==
6.1	57
	58	This system enhances:
	59
7.2	60	* Research: By stratifying patients, reduces cohort heterogeneity in clinical trials.
6.1	61	* Clinical Practice: Provides dynamic diagnostic annotations with timestamps for longitudinal tracking.
	62
5.1	63	== Who has access? ==
1.1	64
4.2	65	We welcome contributions from the global community. Let’s build the future of neurological diagnostics together!
4.4	66
10.1	67	== How to Contribute ==
4.4	68
	69	* Access the `/docs` folder for guidelines.
	70	* Use `/code` for the latest AI pipelines.
	71	* Share feedback and ideas in the wiki discussion pages.
5.1	72
10.1	73	== Key Objectives ==
5.1	74
	75	* Develop interpretable AI models for diagnosis and progression tracking.
	76	* Integrate data from Human Phenotype Ontology (HPO), Gene Ontology (GO), and other biomedical resources.
	77	* Foster collaboration among neuroscientists, AI researchers, and clinicians.
1.1	78	)))
	79
	80
	81	(% class="col-xs-12 col-sm-4" %)
	82	(((
	83	{{box title="Contents"}}
	84	{{toc/}}
	85	{{/box}}
	86
10.1	87	== Main contents ==
4.4	88
5.1	89	* `/docs`: Documentation and contribution guidelines.
	90	* `/code`: Machine learning pipelines and scripts.
	91	* `/data`: Sample datasets for testing.
	92	* `/outputs`: Generated models, visualizations, and reports.
1.1	93	)))
	94	)))